ANTX (AN2 Therapeutics Inc) קפיטליזציה חשבונאית

AN2 Therapeutics, Inc. (ANTX) develops antibiotics for the treatment of prolonged pulmonary pathologies, ensuring an extended period of exclusive market ownership. This price chart illustrates the asset's dynamics, with its value currently at 0.08. The company is currently relying on investment capital to conduct medical trials of its oral medications. Patent protection creates a robust barrier, although business success depends on the pace of clinical research.

For the biopharmaceutical sector of AN2 Therapeutics, Inc. (ANTX), where success depends on high-risk drug trials, assessing the real value of net assets minus all liabilities is critical. By analyzing the book capitalization, an investor determines the business's actual capital adequacy, which allows for an assessment of the issuer's resilience to financial shocks and the probability of bankruptcy in the absence of new funding infusions.